MXPA01007760A - Compuesto adyuvante inmunologico. - Google Patents

Compuesto adyuvante inmunologico.

Info

Publication number
MXPA01007760A
MXPA01007760A MXPA01007760A MXPA01007760A MXPA01007760A MX PA01007760 A MXPA01007760 A MX PA01007760A MX PA01007760 A MXPA01007760 A MX PA01007760A MX PA01007760 A MXPA01007760 A MX PA01007760A MX PA01007760 A MXPA01007760 A MX PA01007760A
Authority
MX
Mexico
Prior art keywords
novel
immunological adjuvant
compounds
adjuvant compound
adjuvant
Prior art date
Application number
MXPA01007760A
Other languages
English (en)
Inventor
Lynn D Hawkins
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of MXPA01007760A publication Critical patent/MXPA01007760A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a compuestos novedosos que funcionan como adyuvantes inmunologicos al co-administrarse con antigenos, tales como vacunas para enfermedades bacterianas y virales, a formulaciones adyuvantes novedosas que incluyen por lo menos uno de los compuestos adyuvantes de la invencion, a composiciones inmunoestimuladoras novedosas que comprenden un antigeno y por lo menos uno de los compuestos adyuvantes de la invencion, asi como a metodos para la inmunizacion de un animal mediante la co-administracion de un compuesto de la invencion con un antigeno contra el cual va a inmunizarse al animal.
MXPA01007760A 1999-02-01 2000-02-01 Compuesto adyuvante inmunologico. MXPA01007760A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
PCT/US2000/002755 WO2000044758A1 (en) 1999-02-01 2000-02-01 Immunological adjuvant compound

Publications (1)

Publication Number Publication Date
MXPA01007760A true MXPA01007760A (es) 2003-06-24

Family

ID=22376670

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA01007760A MXPA01007760A (es) 1999-02-01 2000-02-01 Compuesto adyuvante inmunologico.

Country Status (21)

Country Link
US (1) US6290973B1 (es)
EP (2) EP1439184B1 (es)
JP (1) JP4698027B2 (es)
KR (1) KR100711561B1 (es)
AT (2) ATE269341T1 (es)
AU (2) AU768574B2 (es)
BR (1) BRPI0007936B8 (es)
CA (1) CA2361582C (es)
DE (2) DE60011571T2 (es)
DK (1) DK1147117T3 (es)
ES (2) ES2223464T3 (es)
FI (1) FI120689B (es)
HK (2) HK1070372A1 (es)
HU (1) HU226869B1 (es)
IL (3) IL144671A0 (es)
MX (1) MXPA01007760A (es)
NO (1) NO329111B1 (es)
NZ (1) NZ513259A (es)
PT (1) PT1147117E (es)
WO (1) WO2000044758A1 (es)
ZA (1) ZA200106487B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US7915238B2 (en) * 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
BR0010605A (pt) * 1999-04-28 2002-02-13 Aventis Pharma Gmbh Derivados ácidos de di-aril como ligantes de receptores ppar
JP4230765B2 (ja) 2000-07-31 2009-02-25 エーザイ株式会社 免疫アジュバント化合物、組成物、およびその使用方法
YU66103A (sh) * 2001-01-23 2006-05-25 Aventis Pasteur Vakcina multivalentnog konjugata meningokokalnog polisaharid-proteina
JP2005507953A (ja) * 2001-03-08 2005-03-24 ザ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・ペンシルベニア 抗感染剤としての表面的に両親媒性のポリマー
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
CA2486967A1 (en) * 2002-05-24 2003-12-04 Neopharm, Inc. Cardiolipin compositions their methods of preparation and use
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
JP3900343B2 (ja) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 （ｒｏ）（ｒ’ｏ）（ｒ’’ｏ）ｍ＝ｏの製造方法
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP2263687B1 (en) * 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions containing phospholipid
KR101241176B1 (ko) 2003-03-17 2013-03-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 표면적으로 양쪽성인 중합체 및 올리고머 및 이의 용도
CN1798548B (zh) 2003-06-02 2010-05-05 诺华疫苗和诊断公司 基于含吸附类毒素和含多糖抗原微粒体的免疫原性组合物
US7202234B2 (en) 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
WO2005072246A2 (en) * 2004-01-23 2005-08-11 The Trustees Of The University Of Pennsylvania Facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers and uses thereof
WO2006093813A2 (en) * 2005-02-25 2006-09-08 THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA et al. Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
US7976852B2 (en) 2005-04-26 2011-07-12 Eisai R&D Management Co., Ltd. Compositions and methods for cancer immunotherapy
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
EP2292628A3 (en) * 2005-06-30 2011-05-11 Eisai R&D Management Co., Ltd. Compounds for preparing immunological adjuvant
JP2011506334A (ja) 2007-12-07 2011-03-03 ノバルティス アーゲー 免疫応答を誘導するための組成物
BRPI0821157B8 (pt) 2007-12-18 2021-05-25 Eisai R&D Man Co Ltd processos de síntese de um precursor sintético para o adjuvante imunológico e6020, via beta-ceto amida, seus compostos e compostos cristalinos
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
AU2012312654B2 (en) 2011-09-19 2017-04-13 Gencia Corporation Modified creatine compounds
EP2844303B1 (en) * 2012-05-03 2021-09-15 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
WO2014144777A2 (en) * 2013-03-15 2014-09-18 Beth Israel Deaconess Medical Center, Inc. Lipids that increase insulin sensitivity and methods of using the same
CA2953747A1 (en) 2013-06-28 2014-12-31 Auckland Uniservices Limited Amino acid and peptide conjugates and conjugation process
SG11201704962WA (en) 2014-12-23 2017-07-28 Margaret Anne Brimble Amino acid and peptide conjugates and uses thereof
BR112018017174A2 (pt) 2016-02-26 2019-01-02 Auckland Uniservices Ltd conjugados de aminoácido e peptídeo e processo de conjugação
WO2017214527A1 (en) 2016-06-10 2017-12-14 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (fahfas) for use in the treatment of type 1 diabetes
CA3165957A1 (en) 2020-01-24 2021-07-29 Thomas K. EQUELS Methods, compositions, and vaccines for treating a virus infection
CN113307824B (zh) * 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993004672A1 (en) 1991-09-11 1993-03-18 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
DE4499552C1 (de) * 1993-12-09 1997-07-17 Heinrich Dr Exner Adjuvans für Antigene, Verfahren zur Herstellung und Verwendung
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof

Also Published As

Publication number Publication date
EP1439184A1 (en) 2004-07-21
EP1147117B1 (en) 2004-06-16
AU2867500A (en) 2000-08-18
HUP0105473A3 (en) 2003-11-28
HU226869B1 (en) 2010-01-28
FI120689B (fi) 2010-01-29
EP1439184B1 (en) 2010-06-16
NO329111B1 (no) 2010-08-30
NO20013749L (no) 2001-09-25
HK1043132B (zh) 2005-04-01
HUP0105473A2 (hu) 2002-04-29
ATE471328T1 (de) 2010-07-15
DK1147117T3 (da) 2004-10-25
US6290973B1 (en) 2001-09-18
DE60044570D1 (de) 2010-07-29
ZA200106487B (en) 2002-08-07
NO20013749D0 (no) 2001-07-31
ES2347428T3 (es) 2010-10-29
HK1043132A1 (en) 2002-09-06
ATE269341T1 (de) 2004-07-15
KR100711561B1 (ko) 2007-04-27
EP1147117A1 (en) 2001-10-24
DE60011571T2 (de) 2005-08-18
BRPI0007936B8 (pt) 2021-05-25
AU768574B2 (en) 2003-12-18
IL144671A0 (en) 2002-05-23
JP4698027B2 (ja) 2011-06-08
CA2361582A1 (en) 2000-08-03
BR0007936B1 (pt) 2015-03-10
HK1070372A1 (en) 2005-06-17
KR20010101912A (ko) 2001-11-15
IL174413A0 (en) 2009-02-11
AU2004201147A1 (en) 2004-04-22
WO2000044758A1 (en) 2000-08-03
NZ513259A (en) 2004-05-28
BR0007936A (pt) 2002-04-09
ES2223464T3 (es) 2005-03-01
PT1147117E (pt) 2004-10-29
AU2004201147B2 (en) 2008-04-03
FI20011593A (fi) 2001-07-31
DE60011571D1 (de) 2004-07-22
JP2002535411A (ja) 2002-10-22
IL144671A (en) 2006-07-05
CA2361582C (en) 2010-04-06

Similar Documents

Publication Publication Date Title
MXPA01007760A (es) Compuesto adyuvante inmunologico.
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
MXPA04002490A (es) Interleucina-12 como adyuvante de vacuna veterinaria.
PT1104306E (pt) Composicoes de cpg e adjuvantes de saponina e seus metodos
WO2000057917A3 (en) Adjuvant compositions and methods for enhancing immune responses to polynucleotide-based vaccines
NZ596870A (en) Vaccine compositions comprising a saponin adjuvant
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
AU2001284354A1 (en) Immunological adjuvant compounds, compositions, and methods of use thereof
WO2001097841A3 (en) Qs-21 and il-12 as an adjuvant combination
EA200800917A1 (ru) Адъюванты для вакцин
EP1395283A4 (en) HETEROLOGOUS PROTECTION INDUCED BY IMMUNIZATION WITH INVAPLEX VACCINE
WO2003083083A3 (en) Methods of using flt3-ligand in immunization protocols
AU3478393A (en) Vaccine containing acemannan as an adjuvant
MY141983A (en) Hepatitis b virus surface antigen as a mucosal immunoenhancer, resulting formulations
MX2009000717A (es) Composicion para vacuna y metodo para inmunizacion.
AU6761301A (en) Adjuvant composition comprising fha protein or fragment of fha protein in free form
WO2002004497A3 (en) Multiple antigenic peptides immunogenic against streptococcus pneumoniae
PL341541A1 (en) Isolated strains of staphyloccoccus aureus and vaccines prepared of them
WO2006109186A3 (en) Early endosome neutralising compouds as vaccine adjuvants
WO2002085409A3 (en) Methods and compositions for inducing an immune response to an antigen
WO2003040163A3 (en) Immunomodulating saponins, a method for their preparation and their use for vaccines

Legal Events

Date Code Title Description
FG Grant or registration